A long-term extension study of AG-1749 in patients on concomitant long-term low-dose aspirin therapy
Phase 3
- Conditions
- Prevention of onset of low dose aspirin related gastric ulcer
- Registration Number
- JPRN-jRCT2080220830
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Patients who have finished the preceding confirmatory anti-ulcer efficacy study
2. Patients who are on oral low-dose aspirin at the time of consent and who require continued long-term use of low-dose aspirin even after the start of study treatment in this study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method